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Mild cognitive impairment (MCI) may take several forms, and amnestic MCI (aMCI) has been recognized as an early stage
of Alzheimer’s Disease (AD). Impairment in executive functions including attention (eMCI) may be indicative of several
neurodegenerative conditions. Executive impairment is frequently found in aMCI, it is signiﬁcant for prognosis, and patients with
eMCI may go on to develop AD. Recent studies have found changes in white matter integrity in patients with eMCI to be more




The diagnosis of MCI due to AD (the symptomatic pre-
dementia phase of AD) has been recently proposed by the
National Institute on Aging and the Alzheimer’s Association
[1]. Diagnostic criteria include concern regarding a change
in cognition, impairment in one or more cognitive domains,
preservation of independence in functional abilities, and
not demented. Within the generally accepted framework,
clinical presentations may be in the memory (amnestic) or
nonmemory domains [2].
Clinical studies of prodromal stages to AD tend to focus
onpersonswithamnesticMCI(aMCI).BoththeAlzheimer’s
DiseaseNeuroimagingInitiative(ADNI)andtheMayoclinic
cohorts typify this population. In the Mayo clinical study of
aging, persons in the age range of 70–89 years are enrolled,
with 2/3 of the MCI group being aMCI [3]. ADNI [4]
enrolls participants between ages 55 and 90, and mean age
for the MCI group is 74.7 years. Researchers from the Mayo
clinic proposed quantitative criteria for identifying MCI
as a prodromal stage to Alzheimer’s disease in 1999 [5].
They stressed the importance of memory impairment and
proposed quantitative criteria specifying the level of memory
deﬁcitrelativetoglobalcognitivefunctioning.InADNI,MCI
is deﬁned as a Clinical Dementia Rating of 0.5, and perfor-
mance on the free recall measure of a neuropsychological
memory test (Logical Memory II) is below a given threshold.
Since the vast majority of the subjects characterized as aMCI
will develop AD, aMCI may be deﬁned as a prodromal
condition of AD [6]. The pathophysiological basis and
prognosis of nonamnestic MCI remains unclear, and the
group is probably heterogenous [6, 7], including patients
with frontotemporal dementia [8], Parkinson’s disease [9],
dementia with Lewy bodies [10], vascular dementia [11],
and neuropsychiatric conditions (depression) [12]. Change
in the frontostriatal network supporting executive functions
may occur as a part of healthy aging [13, 14]. Thus, an
M C Is u b g r o u pw i t hi s o l a t e de x e c u t i v ed i ﬃculties may be an
extreme group of normal aging.
The objective of this paper is to review executive/
attentional impairment as an important aspect of MCI or
pre-MCI in terms of symptom manifestation and impor-
tance for disease progression. We will focus on recent
research on MRI and genetic markers that may serve to
further understanding of the pathophysiological processes
underlying executive MCI (eMCI) and its relation to AD.2 International Journal of Alzheimer’s Disease
2. ExecutiveDysfunctioninMCI
Attention and executive impairment are frequent and dis-
abling symptoms in MCI when measured with neuropsycho-
logical tests ranging from simple processing speed tasks to
tasks of complex problem solving. The distinction between
clinical tests of attention and test of executive function
is a fuzzy one and they are here treated as on the same
continuum.Thereisnoconsensusonhowexecutivefunction
should be tested in clinical studies [15], and studies that take
into consideration developments in cognitive psychology
[16] ﬁnd high frequency of executive impairment in both
amnestic and nonamnestic MCI [17], with some subfunc-
tions more aﬀected than others.
Alzheimer’s disease (AD) is the most common cause of
dementia and accounts for approximately 60–70% of all
dementia cases [18], and deﬁcits of episodic memory are a
cognitive hallmark of the disease [19]. Executive dysfunction
is evident in the prodromal stage of AD [20–22] and appears
predominantly in tasks requiring cognitive ﬂexibility, inhi-
bition, and self-monitoring [23]. There is evidence that the
commonly reported impaired ability to perform two tasks
simultaneously in AD reﬂects a speciﬁc deﬁcit in dividing
attention, rather than the result of a more general processing
speed deﬁcit [24]. According to the model of cognitive
decline leading to AD presented by Perry and colleagues
[25], executive problems appear after memory problems in
time, but before typical parietal lobe symptoms (aphasia,
visuospatial deﬁcits). When executive dysfunction is present,
ithasaclearnegativeinﬂuenceonabilitytomanageactivities
of daily living and may thus add to the risk of conversion
from MCI to AD [26]. Predictive accuracy for conversion
fromMCItoADforonesetofcognitivevariables(composed
of episodic memory and processing speed measures) has
been found to be as high as 0.86 (sensitivity, 0.76; speciﬁcity,
0.90) [27]. Gomar et al. [28] found that a test of executive
function and assessment of baseline functional capacity
predicted conversion from MCI to AD after 2 years better
than biomarkers (MR and CSF).
3. ExecutiveNonamnestic MCI
Both aMCI and attention/executive MCI subtypes have been
regarded as important predementia subtypes, at risk for AD
[29]. While aMCI is usually deﬁned as a prodromal, at-risk
condition of AD [30], isolated executive dysfunction can be
a prodromal stage for several neurodegenerative diseases. In
cases of predementia AD, it is not clear if aMCI and eMCI
may be two diﬀerent categories/subtypes of AD or represent
diﬀerent phases of AD development.
If attention/executive MCI is not a distinct AD subtype,
but an earlier stage of AD than aMCI, then aMCI should be
expected to have executive/attentional deﬁcits in addition to
memory impairment. It has been reported that attention and
executivefunctionsmaybeimpairedintheincipientstagesof
AD and may contribute to the observed memory deﬁcit [31].
It has been argued that even patients deﬁned as “pure” aMCI
on screening tests may have executive impairment, when a
comprehensive neuropsychological examination of executive
cognition is performed [17].
The existence of nonamnestic attention/executive MCI
has been recorded in several MCI studies [29, 32–37],
where a comprehensive neuropsychological test battery has
been utilized for classiﬁcation purposes. The prevalence of
attention/executive MCI willvary widelyin diﬀerent samples
based on recruitment criteria and assessment methods but
h a sb e e nr e p o r t e da sf r o m3t o1 5 %[ 38]. In the sample
studiedbyus[37]attention/executiveMCIwithoutamnestic
deﬁcit constitutes about 30% of the total MCI group, which
on the whole is 10–15 years younger than the ADNI study
group.
In a study of Johnson and colleagues [35], 31 older
adults with pure executive MCI were identiﬁed. Of the 12
executive MCI patients who progressed clinically after two
years, 2 converted to probable dementia with Lewy bodies,
10 retained the clinical diagnosis of MCI, and none reverted
to normal. Patients with single domain executive MCI who
progressed quickly over two years had more temporal lobe
atrophy on MRI and slightly lower scores for visual memory
recall when compared to the stable executive MCI patients,
possiblysuggestingthatconvertersmaybeattheirlaterstages
of clinical progression. The executive MCI patients who
progressed reported fewer dysexecutive symptoms than non-
progressors, while there were no diﬀerences in informant-
rated dysexecutive symptoms and baseline performance on
all four executive tests.
Nine subjects with pure attention/executive MCI were
identiﬁed in the longitudinal study of Whitwell and col-
leagues [29]. In this study, almost 70% of MCI patients
within an attention/executive subgroup progressed to
dementia in the period of four years, suggesting that the
group is at high risk of developing dementia. Three patients
converted to dementia with Lewy bodies and three patients
converted to AD dementia. The prognosis for other patients
with isolated attention/executive dysfunction in the study
of Whitwell and colleagues is not clear, but they may also
convert to other dementias or remain stable over many years.
By using similar criteria for classiﬁcation of subjects as
those used in the study of Whitwell and colleagues, we
have identiﬁed a bigger group of 23 nonamnestic attention/
executive MCI patients [37]. A longitudinal followup will
show how many patients will develop AD and other demen-
tias.
4. BrainImaging—MRI Morphometry and
Diffusion Tensor Imaging
The attention and executive functions depend on distributed
networks [39], encompassing both frontal and parietal
associative cortices, as well as subcortical structures and
white matter (WM) pathways [40]. The executive functions
control and monitor task performance and depend criti-
cally on the frontal lobes. Three fronto-subcortical circuits
(originating in the prefrontal cortex) have been identiﬁed
as responsible for executive control functions, that is, the
dorsolateral prefrontal cortex (working memory), the lateralInternational Journal of Alzheimer’s Disease 3
orbital cortex (inhibition), and the anterior cingulate cortex
(response conﬂict) [41, 42].
Degeneration of the medial temporoparietal memory
network is typical for AD [43]. Findings from functional
imaging indicate that during prodromal AD, the brain
network involving the dorsolateral prefrontal cortex and
the anterior cingulate, is aﬀected [44]. Alterations in these
regions have been associated with impairments in executive
functions [45]. While aMCI is characterized by medial
temporal lobe aﬀection [29], atrophy in the basal forebrain
has been found to be characteristic for the MCI groups with
isolated attention/executive deﬁcits [29, 33].
Some studies have reported an association between
prefrontal cortical changes and attention/executive impair-
ment in MCI [29, 34, 46]. Signiﬁcant cortical atrophy in
frontal regions [47]h a sb e e nf o u n di np r e d e m e n t i aA D .I t
hasbeenarguedthatprefrontaldamage,incombinationwith
cingulate damage, has predictive value for the conversion
from MCI to AD [48]. Another recent study indicates that
white matter (WM) pathology in AD is distributed in all
lobesofthebrainbutitismostprominentinthefrontalWM
[49]. In addition to frontal WM changes, MCI patients may
have WM changes in both anterior [50] and posterior [51]
cingulate regions. The anterior cingulate region is regarded
as belonging to a network responsible for executive control
function while the posterior cingulate belongs to a memory
network [52]. Thus, it has been hypothesized that the caudal
portion of the anterior cingulate plays a major role in
executive function abilities, primarily through its reciprocal
connections with the prefrontal cortex [53, 54].
In our recent study on attention/executive MCI [37],
we have demonstrated consistent relationships between neu-
ropsychological function and the microstructural properties
of the WM brain pathways measured by diﬀusion tensor
imaging(DTI),aswellascortical-morphometricparameters.
Executive impairment in MCI patients with unaﬀected
memory performance has been associated with reduced
WM tract integrity (increased radial diﬀusion (DR) and
mean diﬀusivity (MD)) in frontal and cingulate regions
and cortical thinning in caudal middle frontal region. We
have found that WM DR/MD increases in frontal, cingulate,
and entorhinal regions in patients with attention/executive
MCI, but cortical thickness was not diﬀerent from controls
in any of the studied regions [37]. The ﬁndings may thus
indicate that the relative importance of grey matter versus
WM changes may diﬀer at diﬀerent stages of predementia
cognitive impairment [55, 56].
Frontal and temporal WM diﬀusivity changes have
been previously described in aMCI patients [57]. By using
DTI to characterize executive networks in MCI, we found
WM DR/MD changes in both the anterior and posterior
cingulate regions in eMCI suggesting that both regions may
contribute to attention/executive impairment in MCI [36].
The cingulate cortex projects into the striatum [42], and
both the anterior and posterior cingulate cortices receive
mediodorsal thalamic aﬀerents [48], which are part of
fronto-subcortical circuits, involved in executive function.
Some attention/executive subfunctions correlated signiﬁ-
cantly with imaging ﬁndings in frontal and cingulate regions
in the eMCI group, but no signiﬁcant correlations were
found in the controls. In attention/executive MCI, response
inhibition was associated with WM DR/MD underlying the
superior frontal cortex, and response inhibition/switching
was associated with WM DR/MD underlying the superior
frontal, rostral middle frontal, lateral/medial orbitofrontal,
and retrosplenial cortices. Test scores for attention and
divided attention were associated with the cortical thinning
of the caudal middle frontal region. The study results thus
support the results from previous MCI studies, where asso-
ciations between prefrontal changes and attention/executive
impairment have been reported [29, 34, 46]. In addition,
the results conﬁrm that cingulate changes are associated with
executive impairment in MCI [48].
In one recent study [34], MCI patients with isolated
executivedysfunctionhadcerebralhypoperfusioninbilateral
middle frontal cortex, bilateral posterior cingulated, and
the left precuneus relative to controls. Relative to aMCI
patients, eMCI patients had hypoperfusion in the left middle
frontalcortex,leftposteriorcingulate,andtheleftprecuneus,
supporting the existence of pathophysiologically distinct
MCI subgroups.
In the study of Pa and colleagues [33], executive non-
amnestic MCI subgroup had signiﬁcantly less grey matter in
the left dorsolateral prefrontal cortex compared with control
subjects. The eMCI subgroup had less volume in the caudate
nucleus compared with aMCI group, but the diﬀerences for
prefrontal cortex in eMCI versus aMCI were not signiﬁcant,
which could be due to some reduction of prefrontal cortex
volume in aMCI as well. In contrast, the aMCI patients had
less volume in the right inferior parietal cortex, typical for
AD, than eMCI. These neuroimaging ﬁndings also suggest
that some of the eMCI patients may represent a distinct
subgroup of MCI.
We have found increased entorhinal WM DR and MD
in both patients with memory impairment and those with
attention/executive dysfunction without objective memory
impairment [37, 58], suggesting a common aﬀection of
regions known to show changes in early AD. Atten-
tion/executive MCI may be an earlier stage of AD than
aMCI and the patients with nonamnestic attention/executive
impairment may develop memory problems later. It is also
possible that patients with attention/executive MCI may
progress to non-AD dementias or AD with disproportionate
neuropathology in the frontal cortex.
5.Nonmemory FindingsAssociatedwith
Ge neticR isko fAD
To study very early development of AD, neurobiological
markers of high risk in asymptomatic individuals may be
u s e d .S p e r l i n ge ta l .[ 59] use the term AD-P to denote patho-
physiological factors that are signiﬁcant for the development
of clinical AD (AD-C), but each factor in isolation does
not cause AD-C. Candidates for markers may be molecular
or genetic. Amyloid accumulation may be measured with
positron emission tomography (PET) or with cerebrospinal
ﬂuid (CSF) analyses, but both are invasive and costly
procedures that are not suitable for screening. Genetic risk4 International Journal of Alzheimer’s Disease
can be assessed relatively simply, and followup studies of
healthy at risk populations are not prohibitively expensive
although they have ethical problems.
Apolipoprotein E (APOE) and e4 allele carrier status
confer a signiﬁcant increase in risk of developing AD [60].
Recent studies of relative risk based on large samples [61]
argue that the impact of APOE e4 on AD risk is similar to
that of major genes in Mendelian diseases and comparable
to genetic risk of breast cancer. Amyloid load in cognitively
normalpersonsaboveage60correlatespositivelywithAPOE
e4 [62]. In MCI patients PIB-positive PET scans are more
frequent in APOE e4 carriers [63]. In patients with AD,
progression of cerebral amyloid load is associated with e4
gene dose [64]. There is thus evidence that a major genetic
risk factor for AD is associated with preclinical accumulation
of beta amyloid, the most signiﬁcant pathophysiological
causal factor for developing AD. Greenwood et al. [65]h a v e
argued that in view of the complexity of APOE mechanisms
aﬀecting cognition, it would be misleading to view all
cognitive eﬀects of e4 as evidence of incipient AD, and they
argue that in normal aging there is an accumulating eﬀect
of ineﬃcient neural repair mechanisms associated with the
e4 allele. These changes make the brain more vulnerable to
pathological processes, including accumulation of amyloid
beta 42 in AD, but do not cause this process to occur in all
e4 carriers.
Severe cholinergic changes are found in advanced AD,
with loss of cholinergic neurons and receptors [66, 67].
DeKosky et al. [68] found that cholinergic systems are
upregulated in MCI individuals. The authors propose that
the loss of this apparent compensatory response may mark
the conversion of MCI to diagnosable AD. Recent evidence
indicates that complex interactions between APOE e4 and
cholinergic genes (BuChE) aﬀect the conversion rate of MCI
to AD [69] and that the level of beta amyloid accumulation
in the brain is related to both APOE and cholinergic activity
[70, 71]. Thus we see evidence of a negative interaction
between APOE, beta amyloid accumulation, and cholinergic
dysfunction.
There have been numerous studies of cognitive symp-
tomsassociatedwithAPOEe4carrierstatusinnondemented
persons. Wisdom et al. [72] used a meta analysis of more
than 2000 participants and found signiﬁcant positive eﬀect
size for memory and global intellectual function. The
eﬀect sizes are moderate, and the studies are inﬂuenced
by choice of methods, especially in nonmemory cognitive
domains. Parasuraman and collaborators [73]h a v et a k e na
cognitive neuroscience approach to study eﬀects of genes
involved in risk of AD (APOE) or mechanisms involved in
cognitive deﬁcit in AD (cholinergic genes—CHRNA4). They
concluded that intact focusing and impaired disengagement
of visuospatial attention may be linked to dysfunction in
early AD of corticocortical networks linking the posterior
parietal and frontal lobes. Greenwood et al. [74] found that
healthy middle-aged adults without dementia who carry the
APOE e4 allele show deﬁcits in spatial attention and working
memory that are qualitatively similar to those seen in
clinically diagnosed AD patients. This ﬁnding is replicated in
an independent sample by Espeseth et al. [75]. The ﬁndings
support an association between APOE polymorphisms and
speciﬁc components of visuospatial attention. Later studies
have extended the ﬁndings to working memory measured
by operation span [76]. Greenwood et al. [65] used an
experimental paradigm measuring working memory for dot
locations in a spatial array and found that accuracy was
reduced in healthy e4 homozygotes, of mean age 57–60.
Reinvang et al. [77] found that e4 carriers performed worse
on letter-number span, another working memory task, and
in addition on the Stroop color-word interference task. The
groups did not diﬀer in tasks of episodic memory.
Wishart et al. [78] studied cortical activation pattern in
a working memory task and the e4 group showed greater
activity during working memory in the medial frontal and
parietal regions bilaterally and in the right dorsolateral
prefrontal cortex. There were no regions in which the
e3 group showed greater activation than the e4 group.
By measuring event-related potentials (ERPs) while MCI
patients 50–76 years of age worked on an experimental
attention task (auditory three-stimulus oddball). Reinvang
et al. [77] performed an event related potential (ERP)
study with MCI patients and found attenuated N1 and N2
amplitudes in e4 carriers. In a follow up study with only
normal controls covering the same age range working on
the same auditory oddball task, e4 carriers also had reduced
N1 amplitudes. Furthermore, N2 latency was longer for e4
carriers, and this latency predicted memory decline 3.5 years
later, suggesting that attention-related functions may presage
memory decline in those with elevated risk for AD [80]. The
later component P3 has been shown to be associated with
APOE in healthy controls. Irimajiri et al. [81]f o u n dr e d u c e d
amplitude among healthy female e4 carriers in auditory task,
and Espeseth et al. [82] found e4-related reduction of visual
P3a amplitudes. Together, these ﬁndings indicate a potential
clinicalsigniﬁcanceofindividualdiﬀerencesintheattention-
related ERP components N1, N2, and P3. These ﬁndings
of APOE-related changes in attention are associated with
APOE-related diﬀerences in brain structure. Espeseth et al.
[83] found that healthy e4 carriers had thicker cortices than
noncarriers in regions of the brain known to be involved in
attentional function. However, an age by APOE interaction
showed that this eﬀect was speciﬁc for the middle-aged
participants. The crosssectional data indicated that there
might be an accelerated thinning of the cortex for e4 carriers,
suggesting that the thicker cortex among the middle-aged
might be associated with a dysfunctional process. Espe-
seth et al. [82] showed that cortical thickness in regions
with signiﬁcant carrier versus noncarrier diﬀrerences was
negatively correlated with P3a amplitudes, suggesting that
the increase in cortical thickness was indeed dysfunctional.
Further support for this interpretation was presented by
Fortea et al. [84, 85] who showed that while symptomatic
PSEN1 mutation carriers had widespread cortical thinning
compared to healthy controls, asymptomatic mutation carri-
ers had thicker cortices, suggesting that high risk for AD may
be associated with a temporary thickening of the cortex.
Cognitive functions are sensitive to interaction of APOE
with other factors, including interaction with other genes.
Espeseth et al. [75] and Reinvang et al. [86] have arguedInternational Journal of Alzheimer’s Disease 5
that interaction (epistasis) of APOE and CHRNA4, a nico-
tinic receptor gene, inﬂuences function in the domains of
attention and executive function. CHRNA4 has been shown
to be related to attentional function in several studies [86–
93]. The search for cognitive markers of very early AD,
possibly predating amnestic MCI, should therefore take
account of the cognitive neuroscience literature on the role
of cholinergic systems in attention and executive function.
Furthermore,tasksfromcognitiveneuroscienceresearchthat
have proven to be related to speciﬁc cortical-subcortical
activation patterns or neurotransmitter systems may in
general be more sensitive to subtle cognitive changes than
tests derived from clinical studies of advanced pathology.
6. Discussion
Problems of attention and executive function are common in
MCI, and in patients with aMCI they are the most important
additional symptom domain in multidomain aMCI. It is
generallybelievedthatinthisgroup,executivedeﬁcitappears
after memory impairment in the sequence of cognitive
decline leading to full blown dementia.
Executive MCI may occur without memory impairment,
and there is evidence that although etiology is heterogenous,
a signiﬁcant proportion of these patients develop AD. How
large this group is in MCI samples varies and is dependent
on several factors. The strong focus on memory problems
as key symptom in early AD, and the wide normal variation
in attention and executive function in aging, may indicate a
high threshold for these patients to seek medical service. Our
own data indicate that in a relatively young MCI population
investigated with comprehensive neuropsychological testing,
eMCI is a common variant. Attentional and executive dys-
functions may remain undetected even though a thorough
neuropsychologicalexamination isperformed.Diﬃculties in
dividing attention and manipulating remembered informa-
tion may be reﬂected in everyday tasks, such as packing a
bag, keeping track of conversations, or walking whilst talking
[22]. Patients with executive MCI may show increased
behavioral symptoms on questionnaires that speciﬁcally
measure executive behaviors compared with aMCI and
control subjects [33]. Knowing that decreased awareness of
cognitive symptoms has been reported in some patients with
MCI [94] and executive MCI [95], it may be helpful to ask
other informants to rate executive symptoms of the patient.
CurrentconceptionsofearlyMRchangesemphasizehip-
pocampal and cortical atrophy as the signiﬁcant pathological
event, closely linked with emergence of memory impairment
[59, 96]. MR analysis yields sensitive measures of a range
of pathognomonic events, and recent publications from
our group and others indicate that reduced quality of the
connectivity of brain networks may compromise cognitive
function. This is true, both for the memory network of
the brain, including posterior cingulate, and additionally
for frontal networks. These networks are involved in both
memory and nonmemory functions. Our studies and those
of others indicate that in identifying the brain changes
underlying eMCI one should emphasize ﬁber integrity as
measures with DTI as well as frontal lobe cortical thinning.
In their report on the status of preclinical markers, AD
Sperling and collaborators [59] use the concept of Alzheim-
er’s Disease-pathophysiological process (AD-P) to denote
diﬀerent processes that may contribute to development of
clinicalAlzheimer’sDisease(AD-C).Furthermoretheypoint
to studies combining biomarkers (of AD-P) with measures
sensitive to very subtle cognitive decline as clearly needed.
Large-scale longitudinal studies of biomarker-positive pop-
ulations raise enormous problems in terms of ethics, costs,
and logistics. We suggest that healthy APOE e4 carriers are a
realistic and highly relevant study group. Subclinical genetic
eﬀects on MR-morphometry [83], DTI [97], and Default
Mode [98] have been shown. Experimental cognitive studies
have identiﬁed speciﬁc attention and executive subfunc-
tions as sensitive to APOE allele variation. The paradigms
need to be further developed and standardized for use in
clinical/epidemiological studies. This development could be
modeled on the eﬀort to standardize cognitive neuroscience
paradigms for application in schizophrenia research [99].
A great advantage is that they are suited for computerized
administration and scoring, so that one may foresee study
participantsinalongitudinalstudyloggingontotheinternet
and complete a set of standard tasks at regular intervals.
References
[1] M. S. Albert, S. T. DeKosky, D. Dickson et al., “The diagnosis
of mild cognitive impairment due to Alzheimer’s disease:
recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines
for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no.
3, pp. 270–279, 2011.
[2] B.Winblad,K.Palmer,M.Kivipelto,V.Jelic,andL.Fratiglioni,
“Introduction: mild cognitive impairment: beyond controver-
sies, towards a consensus,” Journal of Internal Medicine, vol.
256, no. 3, pp. 181–182, 2004.
[3] R. C. Petersen, R. O. Roberts, D. S. Knopman et al., “Mild
cognitive impairment: ten years later,” Archives of Neurology,
vol. 66, no. 12, pp. 1447–1455, 2009.
[4] R. C. Petersen, P. S. Aisen, L. A. Beckett et al., “Alzheimer’s
Disease Neuroimaging Initiative (ADNI): clinical characteri-
zation,” Neurology, vol. 74, no. 3, pp. 201–209, 2010.
[5] R. C. Petersen et al., “Mild cognitive impairment: clinical
characterization and outcome,” Archives of Neurology, vol. 56,
no. 3, pp. 303–308., 1999.
[6] B. Dubois et al., “Revising the deﬁnition of Alzheimer’s
disease: a new lexicon,” The Lancet Neurology, vol. 9, no. 11,
pp. 1118–1127, 2010.
[7] B. Dubois, H. H. Feldman, C. Jacova et al., “Research criteria
forthediagnosisofAlzheimer’sdisease:revisingtheNINCDS-
ADRDA criteria,” The Lancet Neurology, vol. 6, no. 8, pp. 734–
746, 2007.
[ 8 ]H .J .R o s e n ,J .L e n g e n f e l d e r ,a n dB .M i l l e r ,“ F r o n t o t e m p o r a l
dementia,”NeurologicClinics,vol.18,no.4,pp.979–992,2000.
[9] D. Aarsland, K. Brønnick, and T. Fladby, “Mild Cognitive
Impairment in Parkinson’s Disease,” Current Neurology and
Neuroscience Reports, vol. 11, no. 4, pp. 371–378, 2011.
[ 1 0 ]T .J .F e r m a n ,B .F .B o e v e ,G .E .S m i t he ta l . ,“ R E Ms l e e p
behavior disorder and dementia: Cognitive diﬀerences when
compared with AD,” Neurology, vol. 52, no. 5, pp. 951–957,
1999.6 International Journal of Alzheimer’s Disease
[11] M. Grau-Olivares and A. Arboix, “Mild cognitive impairment
instrokepatientswithischemiccerebralsmall-vesseldisease:a
forerunnerofvasculardementia?”ExpertReviewofNeurother-
apeutics, vol. 9, no. 8, pp. 1201–1217, 2009.
[12] C. H. Wilkins, J. Mathews, and Y. I. Sheline, “Late life depres-
sion with cognitive impairment: evaluation and treatment,”
Clinical Interventions in Aging, vol. 4, no. 1, pp. 51–57, 2009.
[13] R. L. Buckner, “Memory and executive function in aging and
ad: multiple factors that cause decline and reserve factors that
compensate,” Neuron, vol. 44, no. 1, pp. 195–208, 2004.
[ 1 4 ]D .H e a d ,A .Z .S n y d e r ,L .E .G i r t o n ,J .C .M o r r i s ,a n dR .L .
Buckner, “Frontal-hippocampal double dissociation between
normal aging and Alzheimer’s disease,” Cerebral Cortex, vol.
15, no. 6, pp. 732–739, 2005.
[15] D. R. Royall, E. C. Lauterbach, J. L. Cummings et al.,
“Executive control function: a review of its promise and
challenges for clinical research—a report from the Committee
on Research of the American Neuropsychiatric Association,”
Journal of Neuropsychiatry and Clinical Neurosciences, vol. 14,
no. 4, pp. 377–405, 2002.
[ 1 6 ]A .M i y a k e ,N .P .F r i e d m a n ,M .J .E m e r s o n ,A .H .W i t z k i ,
A. Howerter, and T. D. Wager, “The unity and diversity
of executive functions and their contributions to complex
“frontal lobe” tasks: a latent variable analysis,” Cognitive
Psychology, vol. 41, no. 1, pp. 49–100, 2000.
[17] J. Brandt, E. Aretouli, E. Neijstrom et al., “Selectivity of
executive function deﬁcits in mild cognitive impairment,”
Neuropsychology, vol. 23, no. 5, pp. 607–618, 2009.
[18] L. Fratiglioni, L. J. Launer, K. Andersen et al., “Incidence
of dementia and major subtypes in Europe: a collaborative
study of population-based cohorts,” Neurology, vol. 54, no. 11,
supplement, pp. S10–S15, 2000.
[19] G. M. McKhann, D. S. Knopman, H. Chertkow et al.,
“The diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines
for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 7, no.
3, pp. 263–269, 2011.
[ 2 0 ] M .A l b e r t ,M .B .M o s s ,D .B l a c k e r ,R .T a n z i ,a n dJ .J .M c A r d l e ,
“Longitudinal change in cognitive performance among indi-
viduals with mild cognitive impairment,” Neuropsychology,
vol. 21, no. 2, pp. 158–169, 2007.
[21] P.Chen,G.Ratcliﬀ,S.H.Belle,J .A.C auley ,S.T .DeK osky ,and
M. Ganguli, “Cognitive tests that best discriminate between
presymptomatic AD and those who remain nondemented,”
Neurology, vol. 55, no. 12, pp. 1847–1853, 2000.
[22] J. D. Huntley and R. J. Howard, “Working memory in early
Alzheimer’s disease: a neuropsychological review,” Interna-
tional Journal of Geriatric Psychiatry, vol. 25, no. 2, pp. 121–
132, 2010.
[23] L. Traykov, A. S. Rigaud, P. Cesaro, and F. Boller, “Neu-
ropsychological impairment in the early Alzheimer’s disease,”
Encephale, vol. 33, no. 3, part 1, pp. 310–316, 2007.
[24] A.D .Baddeley ,H.A.Baddeley ,R.S.Bucks,andG.K.W ilc ock,
“Attentional control in Alzheimer’s disease,” Brain, vol. 124,
no. 8, pp. 1492–1508, 2001.
[25] R. J. Perry, P. Watson, and J. R. Hodges, “The nature and
staging of attention dysfunction in early (minimal and mild)
Alzheimer’s disease: relationship to episodic and semantic
memory impairment,” Neuropsychologia, vol. 38, no. 3, pp.
252–271, 2000.
[ 2 6 ]D .R .R o y a l l ,E .C .L a u t e r b a c h ,D .K a u f e r ,P .M a l l o y ,K .
L. Coburn, and K. J. Black, “The cognitive correlates of
functional status: a review from the Committee on Research
of the American Neuropsychiatric Association,” Journal of
Neuropsychiatry and Clinical Neurosciences,v o l .1 9 ,n o .3 ,p p .
249–265, 2007.
[27] M. H. Tabert, J. J. Manly, X. Liu et al., “Neuropsychological
prediction of conversion to Alzheimer disease in patients with
mild cognitive impairment,” Archives of General Psychiatry,
vol. 63, no. 8, pp. 916–924, 2006.
[28] J. J. Gomar et al., “Utility of combinations of biomarkers,
cognitive markers, and risk factors to predict conversion from
mild cognitive impairment to Alzheimer disease in patients
in the Alzheimer’s disease neuroimaging initiative,” Archives of
General Psychiatry, vol. 68, no. 9, pp. 961–969, 2011.
[29] J. L. Whitwell, R. C. Petersen, S. Negash et al., “Patterns
of atrophy diﬀer among speciﬁc subtypes of mild cognitive
impairment,” Archives of Neurology, vol. 64, no. 8, pp. 1130–
1138, 2007.
[30] R. C. Petersen et al., “Current concepts in mild cognitive
impairment,” Archives of Neurology, vol. 58, no. 12, pp. 1985–
1992, 2001.
[31] M. Storandt, “Cognitive deﬁcits in the early stages of
Alzheimer’s disease,” Current Directions in Psychological Sci-
ence, vol. 17, no. 3, pp. 198–202, 2008.
[32] A. Nordlund, S. Rolstad, P. Hellstr¨ o m ,M .S j¨ ogren, S. Hansen,
and A. Wallin, “The Goteborg MCI study: mild cognitive
impairment is a heterogeneous condition,” Journal of Neurol-
ogy, Neurosurgery and Psychiatry, vol. 76, no. 11, pp. 1485–
1490, 2005.
[33] J. Pa, A. Boxer, L. L. Chao et al., “Clinical-neuroimaging
characteristics of dysexecutive mild cognitive impairment,”
Annals of Neurology, vol. 65, no. 4, pp. 414–423, 2009.
[34] L. L. Chao, J. Pa, A. Duarte et al., “Patterns of cerebral
hypoperfusion in amnestic and dysexecutive MCI,” Alzheimer
Disease and Associated Disorders, vol. 23, no. 3, pp. 245–252,
2009.
[ 3 5 ]J .K .J o h n s o n ,J .P a ,A .L .B o x e r ,J .H .K r a m e r ,K .F r e e m a n ,
and K. Yaﬀe, “Baseline predictors of clinical progression
amongpatientswithdysexecutivemildcognitiveimpairment,”
Dementia and Geriatric Cognitive Disorders,v o l .3 0 ,n o .4 ,p p .
344–351, 2010.
[ 3 6 ]J .K .J o h n s o n ,B .A .V o g t ,R .K i m ,C .W .C o t m a n ,a n dE .
Head, “Isolated executive impairment and associated frontal
neuropathology,” Dementia and Geriatric Cognitive Disorders,
vol. 17, no. 4, pp. 360–367, 2004.
[37] R. Grambaite et al., “Executive dysfunction in mild cognitive
impairmentisassociatedwithchangesinfrontalandcingulate
white matter tracts,” Journal of Alzheimer’s Disease, vol. 27, no.
2, pp. 453–462, 2011.
[38] A. J. Jak, K. J. Bangen, C. E. Wierenga, L. Delano-Wood,
J. Corey-Bloom, and M. W. Bondi, “Contributions of neu-
ropsychology and neuroimaging to understanding clinical
subtypes of mild cognitive impairment,” International Review
of Neurobiology, vol. 84, pp. 81–103, 2009.
[39] P. A. Reuter-Lorenz and C. Lustig, “Brain aging: reorganizing
discoveries about the aging mind,” Current Opinion in Neuro-
biology, vol. 15, no. 2, pp. 245–251, 2005.
[40] F. Collette, M. Hogge, E. Salmon, and M. Van der Linden,
“Exploration of the neural substrates of executive functioning
by functional neuroimaging,” Neuroscience, vol. 139, no. 1, pp.
209–221, 2006.
[41] R. Cabeza and L. Nyberg, “Imaging cognition II: an empirical
review of 275 PET and fMRI studies,” Journal of Cognitive
Neuroscience, vol. 12, no. 1, pp. 1–47, 2000.International Journal of Alzheimer’s Disease 7
[42] J. L. Cummings, “Frontal-subcortical circuits and human
behavior,” Archives of Neurology, vol. 50, no. 8, pp. 873–880,
1993.
[43] R. L. Buckner and M. E. Wheeler, “The cognitive neuroscience
of remembering,” Nature Reviews Neuroscience, vol. 2, no. 9,
pp. 624–634, 2001.
[ 4 4 ]M .P .M i l h a m ,K .I .E r i c k s o n ,M .T .B a n i c he ta l . ,“ A t t e n t i o n a l
control in the aging brain: insights from an fMRI study of the
stroop task,” Brain and Cognition, vol. 49, no. 3, pp. 277–296,
2002.
[45] G.Bush,B.A.Vogt,J.Holmesetal.,“Dorsalanteriorcingulate
cortex: a role in reward-based decision making,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 99, no. 1, pp. 523–528, 2002.
[46] J. Pa, K. L. Possin, S. M. Wilson et al., “Gray matter
correlates of set-shifting among neurodegenerative disease,
mild cognitive impairment, and healthy older adults,” Journal
of the International Neuropsychological Society,v o l .1 6 ,n o .4 ,
pp. 640–650, 2010.
[ 4 7 ]A .M .H a l l ,R .Y .M o o r e ,O .L .L o p e z ,L .K u l l e r ,a n dJ .T .
Becker, “Basal forebrain atrophy is a presymptomatic marker
for Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 4, no.
4, pp. 271–279, 2008.
[48] B. A. Vogt, Cingulate Neurobiology and Disease,O x f o r d
University Press, New York, NY, USA, 2009.
[49] M. Sj¨ obeck, C. Elfgren, E. M. Larsson et al., “Alzheimer’s
disease (AD) and executive dysfunction. A case-control study
on the signiﬁcance of frontal white matter changes detected by
diﬀusion tensor imaging (DTI),” Archives of Gerontology and
Geriatrics, vol. 50, no. 3, pp. 260–266, 2010.
[50] M.M.Mielk e,N.A.K ozauer ,K.C.G.Chanetal.,“R egionally-
speciﬁcdiﬀusiontensorimaginginmildcognitiveimpairment
and Alzheimer’s disease,” NeuroImage,v o l .4 6 ,n o .1 ,p p .4 7 –
55, 2009.
[51] Y. Zhang, N. Schuﬀ,G .H .J a h n ge ta l . ,“ D i ﬀusion tensor
imaging of cingulum ﬁbers in mild cognitive impairment and
Alzheimer disease,” Neurology, vol. 68, no. 1, pp. 13–19, 2007.
[52] R. L. Buckner, A. Z. Snyder, B. J. Shannon et al., “Molecular,
structural, and functional characterization of Alzheimer’s
disease: evidence for a relationship between default activity,
amyloid, and memory,” Journal of Neuroscience, vol. 25, no.
34, pp. 7709–7717, 2005.
[53] T. Arikuni, H. Sako, and A. Murata, “Ipsilateral connections
of the anterior cingulate cortex with the frontal and medial
temporal cortices in the macaque monkey,” Neuroscience
Research, vol. 21, no. 1, pp. 19–39, 1994.
[54] B. A. Vogt, P. B. Crino, and L. Volicer, “Laminar alterations
in γ-aminobutyric acid(A), muscarinic, and β adrenoceptors
and neuron degeneration in cingulate cortex in Alzheimer’s
disease,”JournalofNeurochemistry,vol.57,no.1,pp.282–290,
1991.
[55] C. R. Jack Jr., V. J. Lowe, S. D. Weigand et al., “Serial PIB and
MRI in normal, mild cognitive impairment and Alzheimers
disease: implications for sequence of pathological events in
Alzheimers disease,” Brain, vol. 132, no. 5, pp. 1355–1365,
2009.
[56] S. M. De la Monte, “Quantitation of cerebral atrophy in
preclinical and end-stage Alzheimer’s disease,” Annals of
Neurology, vol. 25, no. 5, pp. 450–459, 1989.
[57] L. Wang, F. C. Goldstein, E. Veledar et al., “Alterations in
cortical thickness and white matter integrity in mild cogni-
tive impairment measured by whole-brain cortical thickness
mapping and diﬀusion tensor imaging,” American Journal of
Neuroradiology, vol. 30, no. 5, pp. 893–899, 2009.
[58] R. Grambaite, I. Reinvang, P. Selnes et al., “Pre-dementia
memory impairment is associated with white matter tract
aﬀection,” Journal of the International Neuropsychological
Society, vol. 17, no. 1, pp. 143–153, 2011.
[59] R.A.Sperling,P.S.Aisen,L.A.Beckettetal.,“Towarddeﬁning
thepreclinicalstagesofAlzheimer’sdisease:recommendations
from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease,”
Alzheimer’s and Dementia, vol. 7, no. 3, pp. 280–292, 2011.
[ 6 0 ]E .H .C o r d e r ,A .M .S a u n d e r s ,W .J .S t r i t t m a t t e re ta l . ,
“Gene dose of apolipoprotein E type 4 allele and the risk of
Alzheimer’sdiseaseinlateonsetfamilies,”Science,vol.261,no.
5123, pp. 921–923, 1993.
[61] E. Genin, “APOE and Alzheimer disease: a major gene with
semi-dominant inheritance,” Molecular Psychiatry, vol. 16, no.
9, pp. 903–907, 2011.
[62] R. J. Caselli, D. Walker, L. Sue, M. Sabbagh, and T. Beach,
“Amyloid load in nondemented brains correlates with APOE
e4,” Neuroscience Letters, vol. 473, no. 3, pp. 168–171, 2010.
[63] K. E. Pike, G. Savage, V. L. Villemagne et al., “β-amyloid
imaging and memory in non-demented individuals: evidence
for preclinical Alzheimer’s disease,” Brain, vol. 130, no. 11, pp.
2837–2844, 2007.
[64] T. Grimmer, S. Tholen, B. H. Youseﬁ et al., “Progression of
cerebral amyloid load is associated with the apolipoprotein e
ε4 genotype in Alzheimer’s disease,” Biological Psychiatry, vol.
68, no. 10, pp. 879–884, 2010.
[65] P. M. Greenwood, T. Sunderland, C. Lambert, and R. Para-
suraman, “Eﬀects of apolipoprotein E genotype on spatial
attention, working memory, and their interaction in healthy,
middle-aged adults: results from the National Institute of
Mental Health’s BIOCARD study,” Neuropsychology, vol. 19,
no. 2, pp. 199–211, 2005.
[66] P. Davies and A. J. F. Maloney, “Selective loss of central
cholinergic neurons in Alzheimer’s disease,” The Lancet, vol.
2, no. 8000, p. 1403, 1976.
[67] P. J. Whitehouse, D. L. Price, and R. G. Struble, “Alzheimer’s
disease and senile dementia: loss of neurons in the basal
forebrain,” Science, vol. 215, no. 4537, pp. 1237–1239, 1982.
[68] S. T. Dekosky, M. D. Ikonomovic, S. D. Styren et al., “Upreg-
ulation of choline acetyltransferase activity in hippocampus
and frontal cortex of elderly subjects with mild cognitive
impairment,” Annals of Neurology, vol. 51, no. 2, pp. 145–155,
2002.
[69] R. Lane, H. H. Feldman, J. Meyer et al., “Synergistic eﬀect of
apolipoprotein E ε4 and butyrylcholinesterase K-variant on
progression from mild cognitive impairment to Alzheimer’s
disease,” Pharmacogenetics and Genomics,v o l .1 8 ,n o .4 ,p p .
289–298, 2008.
[70] T. Darreh-Shori, A. Forsberg, N. Modiri et al., “Diﬀerential
levels of apolipoprotein E and butyrylcholinesterase show
strong association with pathological signs of Alzheimer’s
d i s e a s ei nt h eb r a i ni nv i v o , ”Neurobiology of Aging, vol. 32,
no. 12, pp. 2320.e15–2320.e32, 2011.
[71] F. Bao, L. Wicklund, P. N. Lacor, W. L. Klein, A. Nordberg,
and A. Marutle, “Diﬀerent β-amyloid oligomer assemblies
in Alzheimer brains correlate with age of disease onset and
impaired cholinergic activity,” Neurobiology of Aging, vol. 33,
no. 4, pp. 825.e1–825.e13, 2012.
[ 7 2 ] N .M .W i s d o m ,J .L .C a ll a h a n ,a n dK .A .H a w k i n s ,“T h ee ﬀects
of apolipoprotein E on non-impaired cognitive functioning: a
meta-analysis,”NeurobiologyofAging,vol.32,no.1,pp.63–74,
2011.8 International Journal of Alzheimer’s Disease
[73] R. Parasuraman, P. M. Greenwood, J. V. Haxby, and C. L.
Grady, “Visuospatial attention in dementia of the Alzheimer
type,” Brain, vol. 115, no. 3, pp. 711–733, 1992.
[74] P. M. Greenwood, T. Sunderland, J. L. Friz, and R. Para-
suraman, “Genetics and visual attention: selective deﬁcits in
healthy adult carriers of the ε4 allele of the apolipoprotein E
gene,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 97, no. 21, pp. 11661–11666,
2000.
[75] T. Espeseth, P. M. Greenwood, I. Reinvang et al., “Interactive
eﬀects of APOE and CHRNA4 on attention and white matter
volume in healthy middle-aged and older adults,” Cognitive,
Aﬀective and Behavioral Neuroscience, vol. 6, no. 1, pp. 31–43,
2006.
[76] V. M. Rosen, J. L. Bergeson, K. Putnam, A. Harwell, and T.
Sunderland, “Working memory and apolipoprotein E: what’s
the connection?” Neuropsychologia, vol. 40, no. 13, pp. 2226–
2233, 2002.
[77] I. Reinvang, I. L. Winjevoll, H. Rootwelt, and T. Espeseth,
“Working memory deﬁcits in healthy APOE epsilon 4 carri-
ers,” Neuropsychologia, vol. 48, no. 2, pp. 566–573, 2010.
[78] H. A. Wishart, A. J. Saykin, L. A. Rabin et al., “Increased brain
activationduringworkingmemoryincognitively intactadults
with the APOE ε4a l l e l e , ”American Journal of Psychiatry, vol.
163, no. 9, pp. 1603–1610, 2006.
[79] I. Reinvang, T. Espeseth, and L. Gjerstad, “Cognitive ERPs are
related to ApoE allelic variation in mildly cognitively impaired
patients,” Neuroscience Letters, vol. 382, no. 3, pp. 346–351,
2005.
[80] T. Espeseth, H. Rootwelt, and I. Reinvang, “Apolipoprotein E
modulates auditory event-related potentials in healthy aging,”
Neuroscience Letters, vol. 459, no. 2, pp. 91–95, 2009.
[81] R. Irimajiri, E. J. Golob, and A. Starr, “ApoE genotype
and abnormal auditory cortical potentials in healthy older
females,”NeurobiologyofAging,vol.31,no.10,pp.1799–1804,
2010.
[82] T. Espeseth, L. T. Westlye, K. B. Walhovd et al., “Apolipopro-
tein E ε4-related thickening of the cerebral cortex modulates
selective attention,” Neurobiology of Aging,v o l .3 3 ,n o .2 ,p p .
304–322.e1, 2012.
[ 8 3 ]T .E s p e s e t h ,L .T .W e s t l y e ,A .M .F j e l l ,K .B .W a l h o v d ,H .
Rootwelt, and I. Reinvang, “Accelerated age-related cortical
thinning in healthy carriers of apolipoprotein E ε4,” Neuro-
biology of Aging, vol. 29, no. 3, pp. 329–340, 2008.
[84] J. Fortea, R. Sala-Llonch, D. Bartr´ es-Faz et al., “Increased
cortical thickness and caudate volume precede atrophy in
psen1 mutation carriers,” Journal of Alzheimer’s Disease, vol.
22, no. 3, pp. 909–922, 2010.
[85] J. Fortea, R. Sala-Llonch, D. Bartr´ es-Faz et al., “Cognitively
preserved subjects with transitional cerebrospinal ﬂuid ß-
amyloid 1-42 values have thicker cortex in Alzheimer’s disease
vulnerable areas,” Biological Psychiatry, vol. 70, no. 2, pp. 183–
190, 2011.
[86] I. Reinvang, A. J. Lundervold, H. Rootwelt, E. Wehling, and T.
Espeseth, “Individual variation in a cholinergic receptor gene
modulates attention,” Neuroscience Letters, vol. 453, no. 3, pp.
131–134, 2009.
[87] T. Espeseth, T. Endestad, H. Rootwelt, and I. Reinvang, “Nico-
tine receptor gene CHRNA4 modulates early event-related
potentials in auditory and visual oddball target detection
tasks,” Neuroscience, vol. 147, no. 4, pp. 974–985, 2007.
[88] T. Espeseth, M. H. Sneve, H. Rootwelt, and B. Laeng,
“Nicotinic receptor gene chrna4interacts withprocessingload
in attention,” PLoS ONE, vol. 5, no. 12, Article ID e14407,
2010.
[89] P. M. Greenwood, J. A. Fossella, and R. Parasuraman, “Speci-
ﬁcity of the eﬀect of a nicotinic receptor polymorphism on
individual diﬀerences in visuospatial attention,” Journal of
Cognitive Neuroscience, vol. 17, no. 10, pp. 1611–1620, 2005.
[90] P. M. Greenwood, M. K. Lin, R. Sundararajan, K. J. Fryxell,
and R. Parasuraman, “Synergistic eﬀects of genetic variation
in nicotinic and muscarinic receptors on visual attention but
not working memory,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 9, pp.
3633–3638, 2009.
[91] P. M. Greenwood, R. Sundararajan, M. K. Lin, R. Kumar,
K. J. Fryxell, and R. Parasuraman, “Both a nicotinic single
nucleotide polymorphism (SNP) and a noradrenergic SNP
modulate working memory performance when attention is
manipulated,” Journal of Cognitive Neuroscience, vol. 21, no.
11, pp. 2139–2153, 2009.
[92] G. Winterer, F. Musso, A. Konrad et al., “Association of
attentional network function with exon 5 variations of the
CHRNA4 gene,” Human Molecular Genetics, vol. 16, no. 18,
pp. 2165–2174, 2007.
[93] R. Parasuraman, P. M. Greenwood, R. Kumar, and J. Fossella,
“Beyond heritability: neurotransmitter genes diﬀerentially
modulate visuospatial attention and working memory,” Psy-
chological Science, vol. 16, no. 3, pp. 200–207, 2005.
[94] A.Vogel,S.G.Hasselbalch,A.Gade,M.Ziebell,andG.Walde-
mar, “Cognitive and functional neuroimaging correlates for
anosognosia in mild cognitive impairment and Alzheimer’s
disease,” International Journal of Geriatric Psychiatry, vol. 20,
no. 3, pp. 238–246, 2005.
[ 9 5 ]J .K .J o h n s o n ,J .P a ,A .L .B o x e r ,J .H .K r a m e r ,K .F r e e m a n ,
and K. Yaﬀe, “Baseline predictors of clinical progression
amongpatientswithdysexecutivemildcognitiveimpairment,”
Dementia and Geriatric Cognitive Disorders,v o l .3 0 ,n o .4 ,p p .
344–351, 2010.
[96] C. R. Jack Jr., D. S. Knopman, W. J. Jagust et al., “Hypothetical
model of dynamic biomarkers of the Alzheimer’s pathological
cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128,
2010.
[97] V. Heise, N. Filippini, K. P. Ebmeier, and C. E. Mackay, “The
APOE epsilon 4 allele modulates brain white matter integrity
inhealthyadults,”MolecularPsychiatry,vol.16,no.9,pp.908–
916, 2010.
[98] N. Filippini et al., “Distinct patterns of brain activity in
young carriers of the APOE-epsilon4 allele,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 106, no. 17, pp. 7209–7214, 2009.
[99] C. S. Carter and D. M. Barch, “Cognitive neuroscience-based
approaches to measuring and improving treatment eﬀects
on cognition in schizophrenia: the CNTRICS initiative,”
Schizophrenia Bulletin, vol. 33, no. 5, pp. 1131–1137, 2007.